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Purpose: To examine international approaches to the ethical oversight and regulation of 
quality improvement and clinical audit in healthcare systems.  
Data sources: We searched grey literature including websites of national research and ethics 
regulatory bodies and health departments of selected countries. 
Study selection: National guidance documents were included from six countries: Ireland, 
England, Australia, New Zealand, the United States of America and Canada. 
Data extraction: Data were extracted from 19 documents using an a priori framework 
developed from the published literature. 
Results:  
We organised data under five themes: ethical frameworks; guidance on ethical review; 
consent, vulnerable groups and personal health data. Quality improvement activity tended to 
be outside the scope of the ethics frameworks in most countries. Only New Zealand had 
integrated national ethics standards for both research and quality improvement.  Across 
countries, there is consensus that this activity should not be automatically exempted from 
ethical review, but requires proportionate review or organisational oversight for minimal risk 
projects.  In the majority of countries, there is a lack of guidance on participant consent, use 





















Conclusion: Where countries fail to provide specific ethics frameworks for quality 
improvement, guidance is dispersed across several organisations which may lack legal 
certainty. Our review demonstrates a need for appropriate oversight and responsive 
infrastructure for quality improvement underpinned by ethical frameworks that build 
equivalence with research oversight. It outlines aspects of good practice, especially The New 

























Quality improvement (QI) is described as ‘systematic, data-guided activities designed to bring 
about immediate, positive changes in the delivery of healthcare in particular settings’ [1]. It 
encompasses a broad range of activities including clinical audit, routine QI and experimental 
QI research. Routine QI activities are considered to be a fundamental part of high quality 
learning healthcare systems [2, 3] ‘in which knowledge generation is so embedded into the 
core of the practice of medicine that it is a natural outgrowth and product of the healthcare 
delivery process and leads to continual improvements in care’ [4].  
The valuable role of QI in driving improvements in service delivery and patient outcomes is 
well accepted [ 5, 6]. However, QI has been described as existing in a grey area between 
clinical practice and health research and distinctions between QI activities, health research 
and clinical practice have become blurred due to rapid changes in health systems, data 
analytics and technological advances. Health care organisations and clinical staff are 
uncertain as to what constitutes QI activities and what is required in terms of ethical 
oversight and by whom [4]. The lack of clear guidance has led to inconsistent ethical review 
decisions, confusion on requirements for participant written consent and use of personal 
health data for secondary analysis [7, 8].  
 Moreover, unlike approaches to health research, there is limited international collaboration 
aimed at achieving consensus on what ethical oversight or frameworks might apply to QI 
activities [8]. The consequences of this is both under and over-regulation that can lead to the 
use of less rigorous study designs in order to avoid the ethical review process or overly 
burdensome criteria that make the evaluation of changes to clinical practice unfeasible [9]. 
The lack of formal ethical frameworks and mechanisms for national oversight also impacts on 
the ability of QI activities to respond to changes in legislation and regulation [10]. To date, 
there has been no attempt to review how different countries address the ethical dimensions 
of QI activities and where these are situated relative to national research ethical frameworks. 
The aim of this review is to examine international approaches to the ethical oversight and 
regulation of QI and clinical audit, including guidance on participant consent and secondary 
use of health data. The review focused on the main health research regulatory bodies and 
government health departments of six purposefully sampled countries: Ireland, England, 
























The focus of this review was national policy and guidance related to ethical frameworks for 
QI activities. A grey literature search plan was developed to incorporate different searching 
strategies, including targeted website searches and customised Google searches. We focused 
on the identification of documents and websites of the main research ethical guidance 
frameworks published by organisations with primary responsibility for research or QI ethical 
guidance in each country. Where a central organisation could not be identified or the 
research ethical framework did not address QI or audit, broader web searches were 
undertaken. Targeted websites included the national research and ethics regulatory bodies 
and the health departments in each country. The following search terms were used, as a 
minimum for each website search: “ethics or ethical”; “audit"; “quality improvement”; and 
“consent”.  
Given the vastness of the grey literature, results were organised based upon relevance and 
the first 10 pages, or 100 hits, were reviewed for each search. Two team members 
independently conducted the search for relevant material and results were discussed with a 
third member.  Inclusion criteria were: primary research ethics documents in each country, 
English language, organisations with a national remit to provide guidance on research or QI 
ethics. (Supplemental file).   
DATA EXTRACTION 
A thematic analysis, based on a hybrid inductive and deductive approach, was used to 
organise and analyse the data from the selected documents [11]. Data were extracted using 
an a priori framework developed from a preliminary review of the literature. The categories 
for data extraction included: country, organisation, national ethics framework, recognition of 
QI/audit, governance on QI, consent, minimal/low risk, vulnerable groups, health data 
(supplementary data). A narrative synthesis of the data is provided with exemplars to 





















We drew on 19 documents or websites across the six countries (Table 1) and one document 
from the European Union that prompted changes in two of the countries [10]. Data sources 
included two legislative Acts [12, 13],  five reports pertinent to countries’ research ethics 
legislative frameworks [14-18, 29], eight guidance documents [10,19-24], and four webpages 
[25-28] (Table 1). The characteristics and variation in ethical guidance between the six 
countries are presented under the following themes: ethical frameworks; guidance on ethical 
review; consent, vulnerable groups and personal health data.  
ETHICAL FRAMEWORKS  
Five of six countries reviewed have a central, independent agency or office with responsibility 
for determining national ethical standards in health research (Table 2). Across the six 
countries there is considerable variability in the way QI activity is recognised within national 
research ethics documents. In England, Canada and the USA, the research ethics frameworks 
explicitly state that QI activities are outside of their scope [13, 14, 18], though there is 
acknowledgement that such activities may raise ethical issues.  Where central agencies do 
not provide ethical guidance, the advice on ethical conduct of QI activities tends to be 
dispersed across several organisations (Table 2).   
The central research ethics bodies in Australia and New Zealand provide specific QI ethical 
guidance. Australia has a separate ethical guidance document for QI activities alongside its 
national framework on ethical conduct in human research [17, 23]. Up to 2019, New Zealand 
took a similar approach [15], but following an extensive review and public consultation, the 
NZ National Ethics Advisory Committee published an integrated ‘National Ethical Standards 
for Health and Disability Research and Quality Improvement’ [16]. This framework articulates 
an expectation that all projects (research or QI) adhere to or exceed the ‘Ethical Standards’ 
[16] and provides a chapter on QI [ 16, pg 216]. 
The NZ model is the exception - in the majority of countries, there remains a reluctance to 
address the ethical ambiguities around QI and audit. This is evident in the recent updates to 
the USA Federal Policy for the Protection of Human Subjects, known as the “Common Rule” 
[13]. The advice on QI activities is contained in the ‘Frequently Asked Questions’ section of 
the Office for Human Research Protections (OHRP) website rather than the ‘Common Rule’ 





















GUIDANCE ON ETHICAL REVIEW 
There is a consensus across the six countries that when a QI activity is considered minimal 
risk, it ‘normally or ‘typically’ does not require ethical review by Research Ethics Committee 
(REC) or Institutional Review Board (IRB) [14, 16, 19, 21, 23, 27]. However, there is no 
standardised definition of minimal risk (supplemental file). Addressing this point, NZ and 
Australia provide a list of criteria that indicate when a project may pose more than minimal 
risk and thus requires ethical review (Table 2).  The criteria include whether a QI activity 
constitutes a departure from usual care, involves human tissue, secondary use of identifiable 
information without consent, or involves vulnerable groups [16, 23]. 
The other four countries use criteria to establish boundaries between QI and research and  
apply broad principles to distinguish between the two [27, 28, 29]. For example, an activity 
may constitute research if one of the following criteria apply: 1) participants are randomised; 
2) the study protocol demands changes to usual care; and 3) the findings are going to be 
generalizable [28]. In the USA, if an activity represents ‘a systematic investigation, including 
research development, testing and evaluation, designed to develop or contribute to 
generalizable knowledge’, it fits the definition of research and requires formal ethics review 
[27].  
Where ethical review is required, the level of oversight necessary, full or expedited review or 
organisational oversight alone, differs across countries. In many cases, QI activities qualify for 
an expedited review by alternative low-risk/quality assurance committees either within the 
healthcare organisation or sub-committees of the ethics committee [14, 23, 27].  
CONSENT 
There is a similar lack of clarity on participant consent where there is little guidance on 
requirements for written consent, verbal consent or notification and provision of information 
alone. NZ is the only country which explicitly sets a standard for consent in relation to QI for 
projects that are considered more than minimal risk:  
‘18.12 Informed consent should be obtained where practicable prior to commencing 
QI activities, preferably in writing. Verbal consent and discussions related to written 




















In the other five countries, the general guidance is that if there is any doubt that an activity 
may constitute research or involves using data beyond the original purpose for which it is 
collected, the default approach is to obtain explicit informed consent from participants.  
All of the reviewed documents suggest that countries are cognisant of not impeding clinically 
important QI activities for patient benefit [ 19, 21, 23, 24, 27]. Most allow for caveats in cases 
where consent may not be feasible or practical to obtain. In Australia, NZ, the USA and 
Canada, an ethics committee may waive the requirement for consent if a number of stringent 
criteria are met. These include the following:  that involvement carries no more than low risk 
to participants;  the public interest in the proposed activity substantially outweighs the public 
interest in the protection of privacy; the research activity is likely to be compromised if the 
participation rate is not near complete; and the requirement for explicit consent would 
compromise the necessary level of participation [13, 14, 16, 23]. 
VULNERABLE GROUPS 
Any QI activity with vulnerable groups, such as individuals with impaired cognition, tends to 
be treated as research regardless of the level of risk associated with the activity. Both 
Australian and New Zealand QI guidelines recommend that any QI activity involving a 
vulnerable group undergo ethical review [16, 23]. While not explicitly stated in the other four 
countries reviewed, the same principles are likely to apply. None of the countries reviewed 
have guidance on low risk QI activity where vulnerable groups are part of larger study 
populations.  
PERSONAL HEALTH DATA 
 There is a general principle among the countries reviewed that if clinical staff have a 
legitimate relationship with the data subjects and the project poses minimal risk then there is 
not a requirement for patients to give explicit consent for their data to be used [12, 22]. This 
is based on the assumption that QI activity is part of good medical practice and the patient’s 
consent to treatment or participation in the health system implies consent to have their data 
used for improvement purposes [13-16, 20, 24].  As countries update general data protection 
legislation to keep pace with digital technology, there are implications for research and QI 
[10,12]. An example of this is the introduction of the General Data Protection Regulation 




















Under GDPR, data protection is a fundamental right for all EU citizens, and any use of 
personal data, including health information, constitutes ‘data processing’ which is subject to 
strict accountability [10].  EU countries individually interpret GDPR requirements through 
country specific legislation [12, 22].  
In anticipation of this legislation, England has introduced a new ethical infrastructure, 
including a national data opt-out service which provides the public with a way of excluding 
their identifiable healthcare information being used for reasons other than their individual 
care [22].  In Ireland, under the Health Research Regulations 2018 [12], all researchers who 
access personal data, including retrospective chart reviews for the purpose of research, are 
required to obtain the explicit consent of all data subjects [25]. The National Office for 
Clinical Audit (Ireland) has provided guidance on the circumstances where clinical audit may 
be exempt from the requirements of explicit consent, but it is informational guidance and 
lacks legal certainty [24]. In the USA, the updates to the ‘Common Rules’ allow for secondary 
use of data without explicit consent when certain criteria apply (supplemental file). Similarly, 
























This is the first publication that summarises and considers national approaches and 
frameworks for QI across countries. Individual country research ethical frameworks are based 
on the ‘Declaration of Helsinki – Ethical Principles for Medical Research Involving Human 
Subjects’ [30] which provides a common language and approach. In contrast, this review 
confirms that there is a lack of ethical frameworks and guidance for QI within individual 
countries and this is also well documented elsewhere [ 2, 3, 7, 8, 9, 31, 32]. Across the six 
countries reviewed, QI activities are conceptually distinguished from health research. Only 
one country, New Zealand, has developed an integrated standards framework for the ethical 
conduct of research and QI.   No country gives a blanket exemption for ethical review to any 
project based on the claim that it is QI activity. However, it is generally accepted that certain 
‘low/minimal risk’ activities can be exempted from full ethical review, though these require 
organisational oversight to ensure compliance with ethical principles [16, 19]. Issues on 
participant consent and the use of personal health data is a concern for the countries 
reviewed, especially in the EU.  
There is a tension in the published literature between some authors who advocate that all QI 
should be treated as research and subject to standard ethical review [ 3, 7] and others who 
propose more proportionate and streamlined systems based on alternative ethics 
frameworks that are focussed on learning in healthcare [2, 33, 34, 35, 36]. In the latter, the 
level of ethical review is based on the risk posed to participants and a waiver of consent is 
possible for low-risk QI activities [2, 3]. In much of this commentary and research there is 
limited engagement with patients and the general public to elicit their views on consent and 
the use of personal health data for QI activities, and in particular the voice of vulnerable 
groups is absent [36,37,38].  
Debates about the ethical standing of QI activities have continued for over 20 years. 
Moreover, as clinical research and clinical practice has become more integrated, a growing 
number of activities that take place in the healthcare system cannot be easily classified as 
research or ‘non-research’ [ 31, 34, 35, 36]. While the majority of countries have well 
established infrastructure to pre-empt the implications of national and international 




















The lack of national QI ethics frameworks has created a vacuum and a deficit in standardised 
and best practice guidance in the governance and regulation of QI. This in turn has given rise 
to a ‘spectrum of ethical issues’ that mainly revolve around conflict between current 
regulatory systems designed for research and the flexibility required by learning health care 
systems that depend on QI [9].  
This review suggests that the New Zealand provision of an integrated National Ethical 
Standards for Research and QI, is a pragmatic solution that could be considered by other 
countries.   When countries place QI ethical guidance outside of their core research ethical 
frameworks and infrastructure they create ambiguity, differences in organisational responses 
and legal uncertainty [ 8, 19, 24, 35]. One of the unintended consequences is that activities 
aimed at improving services and, ultimately, patient safety may become vulnerable to 
disruption with the introduction of new regulations or legislation such as GDPR.  
Limitations 
This was not an exhaustive search of QI guidance documents in the selected countries but it 
does capture the guidance from the main regulatory bodies. There is a need to review QI 
guidance in non-English speaking countries to inform best practice. Our review has not 
captured how countries operationalise the QI guidance or how recent changes has impacted 
on ethical decision making or clinical practice.  
Accepting these limitations, we have made a number of observations to inform this debate 
going forward (Box 1).  
 
Insert Box 1 Observations to promote best-practice on ethics oversight for QI activity 
1. QI and clinical audit should be recognised as core and legitimate activities for 
clinical staff with appropriate national ethics guidance and infrastructure. 
2. To protect patients and clinical staff there is need for national QI ethics frameworks 
and proportionate ethics review structures that balance patient safety and rights 
with service improvement activities. 
3. Overarching governance by a central agency with responsibility for ethical conduct 




















interpretation and compliance with national and international regulation and 
legislation. 
4. Public engagement should form part of the development of national ethics 
frameworks and local guidance. Building public awareness and trust requires 
targeted efforts to improve population health literacy on principles of QI, consent 
and use of personal data to support learning healthcare systems.  
5. Health care organisations need support and infrastructure to provide ethical 
oversight for low-risk, locally driven QI.  Research ethics review boards require 
frameworks to support consistent decision making for QI activity. 
6. In the case of vulnerable groups, guidance is required to ensure that they are not 
excluded from QI activities (especially low-risk activity) while ensuring their rights 




Allowing QI activities to exist in a ‘borderline space’ between clinical practice and research 
leaves it vulnerable to disruption due to changes in regulation and legislation. This in turn 
negatively impacts on health care organisations and clinical staff confidence to lead QI within 
their services.  Our review demonstrates that there is a need for appropriate oversight and 
responsive infrastructure for QI underpinned by ethical frameworks that builds equivalence 
with research. We highlighted good practice in the six countries reviewed which provide 
opportunities for shared learning and the flourishing of QI as a vital part of learning 
healthcare systems.  
 
Data availability: No new data were generated or analysed in support of this review. The 























Table 1: Sources of information from each country 
Country Resources that were used to inform this review 
Ireland Government of Ireland (2018) Data Protection Act 2018 (Section 36(2)) (Health Research) Regulations.  [Legislative Act] [12] 
Health Research Board (2018) Health Research Regulations 2018 FAQ. [Webpage] [25] 
Health Service Executive (HSE) Quality and Patient Safety Directorate (2017) A Practical Guide to Clinical Audit. [Report] [21] 
HSE, National Office of Clinical Audit (2019) GDPR Guidance for Clinical Audit. [Report] [24] 
England  National Health Service Health Research Authority (2017) UK Policy for Health and Social Care Research. [Report, made in 
accordance with the country’s legislative framework] [18, 29]  
Dixon, N., Healthcare Quality Improvement Partnership (2017) Guide to managing ethical issues in quality improvement (QI) 
or clinical audit projects. [Report] [19] 
Healthcare Quality Improvement Partnership (2017) Using Clinical Audit in Commissioning Healthcare Services. [Report] [20] 
National Data Guardian for Health and Care (2016) Review of Data Security,Consent and Opt-Outs. [Report] [22] 
National Health Service (2019) National Data Opt-Out. [Webpage] [26] 
NHS Health Research Authority, The Medical Research Council. Is my study research? [28]] 
Australia National Health and Medical Research Council. (2007, Updated 2018) National Statement on Ethical Conduct in Human 
Research. [Report, made in accordance with a Legislative Act] [17] 
National Health and Medical Research Council. (2014) Ethical Considerations in Quality Assurance and Evaluation Activities. 
[Report] [23] 
New Zealand National Ethics Advisory Committee (2012) National Ethical Standards for Health & Disability Research Ethical Guidelines for 
Observational Studies: Observational research, audits and related activities. Revised edition [Report, made in accordance with 
the country’s legislative framework] [15] 
National Ethics Advisory Committee (2019) National Ethical Standards for Health and Disability Research and Quality 
Improvement [16] 
Canada Canadian Institutes of Health Research (2010), Natural Sciences and Engineering Research Council of Canada, & Social 
Sciences and Humanities Research Council of Canada. Tri-Council Policy Statement. Ethical Conduct for Research Involving 
Humans. [Report, made in accordance with the country’s legislative framework] [14] 




















of Human Subjects (The Common Rule). [Legislative Act] [13] 
US Department of Health and Human Services Office for Human Research Protections. (2018). Quality Improvement Activities 
FAQs. [Webpage] [27] 
European 
Union 
European Union. Regulation (EU) 2016/679 (General Data Protection Regulation). 2016 [10] 
 
 
Table 2: Summary of approaches to ethical oversight of quality improvement and clinical audit activities for each country 
 Ireland England Australia New Zealand USA Canada 
National regulatory 







National Health & Medical 








Advisory Panel on 
Research Ethics * 
 
Is QI activity within the 
scope of the national 
document / framework 
for research ethics?  
No; main guidance is 
contained in the Health 
Service Executive (HSE) 
Quality and Patient Safety 
Directorate (2017) 
No;‘Audit of practice’ 
and ‘service 
evaluation’ are 
exempt from this  
framework (QI not 
mentioned) Section 
3.1 (pg 6) 
 
Main guidance on 
ethical issues related 







‘Ethical considerations in 




Yes; National Ethical 
Standards for Health 
and Disability 




and QI ethics 
framework. Outlines 
standards that are 
applicable for 




No; but limited 
guidance on OHRP 
website 
‘Typically, QI activities 
are not considered 
research subject to the 








‘In relation to QA 
and QI studies…. 
such activities do 
not normally follow 
the ethical and 
consent 
procedures 
outlined in this 
Policy’ 
Is ethical review 
required ? 
Quality Assurance studies, 
clinical audits, and service 
evaluations do not normally 
require Research Ethics 
Committee (REC) review 
 
HQIP: Clinical audit 
or local QI may not 
require review by an 
ethics committee but 
In many situations, 
oversight of the activity is 
required, but ethical 
review is not necessary 
[23].  
 ‘While some level of 




If the purposes of a QI 
activity are limited to (a) 
delivering healthcare, 
and 
 (b) measuring and 
‘..These activities[ 
QA, QI] may still 
raise ethical issues. 
In such instances, 
























 Committee review 
processes are often 
not the optimal 
pathway for review 
of these activities’ 
[16, p20] 
reporting provider 
performance data for 
clinical, practical, or 
administrative uses… 
there is no requirement 
under these regulations 
for such activities to 






than a Research 
Ethics Board (REB). 
Are criteria for 
proportionate ethical 
review / exemption 
from ethical review  
provided 
No; Staff are advised that 
ethical advice should be 
sought if audit practices 
may be considered 
intrusive, sensitive, or if 
there is uncertainty on the 
ethical implications 
Yes: HRA provides 
and online decision 
tool to determine if a 










HQIP lists 7 criteria 
for QI/audit to 
trigger an ethical 
review but this is not 
a national standard. 
(supplemental file)  




1.Infringes the privacy or 
professional reputation of 
participants, providers or 
organisations. 
2.Secondary use of data 
3.Data collection 
beyond clinical need 
4. Comparison of 
cohorts 
5.Testing non- standard 
protocol /equipment 
6.use of randomisation, 
control group 
7. Targeted analysis of 




Yes;  8 criteria 
QI activities are 
generally low risk. 
Some factors that 
may increase ethical 
risk are when: (16 p 
217) 
1.it poses additional 
risks to or burdens 
on a patient and/or 
their family or 
whānau beyond their 
routine care. 
2. the data to be 
collected is of a 
sensitive nature 
3. secondary use of 
data/ 
4.use of identifiable 
data 
5.use of algorithms – 
( related to artificial 
intelligence and 
machine learning ) 
6. it allocates 
interventions 
No specific criteria 
except in above 
definition 
No; These non- REB 





























7. it is unlikely to 
provide direct 
benefits to patients1 
8. it involves body 
parts or bodily 
substances 
 
Is their guidance on 
consent specific to QI? 
Following GDPR: Health 
Research Regulations 
(2018)‘All researchers that 
access personal data for 
health research purposes, 
including retrospective 
chart reviews …, are 
required to obtain the 
explicit consent of all data 
subjects’.  
The National Office for 
Clinical Audit have provided 
guidance on when local or 
national clinical audit may 
not require explicit consent. 
(NOCA 2019) 
No explicit guidance 
for  QI/Audit) 
NHS-HRA:  
Proportionality 
should be applied to 




closer the research is 
to standard practice, 
the less need there is 
to provide patients 
and service users 
with detailed and 
lengthy information 
Not explicit: 
‘Those conducting the 
activity need to consider a 
range of issues including 
consent, privacy, relevant 
legislation’ pg 2 
 Yes,  
Participants should 
be asked for their 
informed consent if a 
quality improvement 
activity imposes 
more than minimal 
risk, as defined by 
categories of risk in 





Waiver of consent: The 
HHS regulations 
protecting human 
subjects allow an IRB to 
waive the requirements 
for obtaining consent 
when:   
1.The risk to the 
subjects is minimal;  
2.Subjects’ rights and 
welfare will not be 
adversely affected by 
the waiver;  
3.Conducting the 
research without the 
waiver is not 
practicable;  
4) If appropriate, 







relation to QI/audit  




















grant a waiver of 
consent for secondary 
use of patient 
information in certain 
circumstances?  
A “national data opt-
out” was introduced 
in England in May 
2018, as a service 
that allows patients 
to opt-out of their 
confidential patient 
information being 









* Comprises Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada, and the Social Sciences and Humanities Research 
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